Average Co-Inventor Count = 7.58
ph-index = 12
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Bayer Healthcare LLC (10 from 780 patents)
2. Bayer Pharmaceuticals Corporation (8 from 70 patents)
3. Allomek Therapeutics LLC (1 from 1 patent)
4. Cheminpharma LLC (1 from 1 patent)
5. Allostem Therapeutics LLC (0 patent)
20 patents:
1. 9034861 - MEK inhibitors useful in the treatment of diseases
2. 8841330 - Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
3. 8338594 - Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
4. 8153785 - Stabilizing ligands for regulation of protein function
5. 8143393 - Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
6. 8129379 - Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
7. 8124630 - ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
8. 7928239 - Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
9. 7897623 - ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors
10. 7648986 - Substituted thieno[3,2-D]pyrimidines as Rho kinase inhibitors
11. 7645878 - Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
12. 7625915 - Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
13. 7528255 - Hydroxy, ω-carboxyaryl substituted diphenyl ureas and dirivatives thereof as raf kinase inhibitors
14. 7517880 - Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
15. 7371763 - Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas